Hypoparathyroidism biotech heads for NASDAQ

I reported previously (Apr 2014) on Israel’s Entera Bio which is testing treatments for disorders in the parathyroid gland, and osteoporosis. Entera Bio has now filed for floating the biotech on NASDAQ to fund Phase II/III trials of its treatment for hypoparathyroidism.

http://www.globes.co.il/en/article-entera-bio-files-for-nasdaq-ipo-1001197354

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *